Genflow Biosciences (LON:GENF / OTCQB:GENFF) has reported encouraging interim results from its SLAB-VET-001 study, giving investors an early look at how its centenarian-derived SIRT6c gene therapy performs in naturally aged dogs. CEO Dr Eric Leire explains why the findings matter, why plasmid DNA has emerged as the preferred veterinary delivery route, how the data are accelerating discussions with animal health companies and why progress in dogs could have wider implications for Genflow’s human sarcopenia programme.
Key Moments
00:09 – SLAB-VET delivers an important milestone
Dr Leire explains why testing SIRT6c in naturally aged dogs marks a significant step.
00:44 – A centenarian-derived gene moves into real-world ageing
Early signs from older animals provide a new test of Genflow’s longevity approach.
01:05 – Why pDNA is leading the veterinary programme
Lower manufacturing costs, scalability and a potentially simpler safety profile underpin the choice.
01:39 – Repeat dosing could strengthen the commercial case
Dr Leire highlights practical advantages over viral-vector delivery.
02:11 – Toronto data draw industry attention
Scientists, delegates and animal health companies focus on changes in biological age and muscle performance.
02:37 – Naturally aged dogs add translational relevance
The study differs from laboratory models engineered to accelerate ageing.
03:11 – Results accelerate licensing discussions
Genflow says the presentation has strengthened engagement with potential commercial partners.
03:33 – Partnering rather than building an animal-health business
The company is targeting licensing, milestone and royalty structures or a potential outright asset sale.
04:19 – Three catalysts investors should watch
Veterinary partnering, patent progress and advancement of the human programmes take centre stage.
04:25 – A veterinary deal could bring non-dilutive value
Management sees partnering as a potential source of capital and external validation for the platform.
04:44 – Europe and Japan patent progress
Genflow expects further intellectual-property milestones around its SIRT6 technology.
05:04 – Sarcopenia moves higher up the agenda
Positive dog data increase the relevance of Genflow’s work targeting age-related muscle decline in humans.
05:30 – Why dogs may matter more than mice
Shared environments and lifestyles could make naturally aged dogs a more relevant translational model.
05:50 – Eye and liver programmes add further optionality
Genflow continues to advance additional therapeutic opportunities beyond sarcopenia.
